Pre-Eclampsia - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pre-Eclampsia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H2 2016', provides an overview of the Pre-Eclampsia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
- The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
- The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pre-Eclampsia Overview 6
Therapeutics Development 7
Pipeline Products for Pre-Eclampsia - Overview 7
Pipeline Products for Pre-Eclampsia - Comparative Analysis 8
Pre-Eclampsia - Therapeutics under Development by Companies 9
Pre-Eclampsia - Therapeutics under Investigation by Universities/Institutes 10
Pre-Eclampsia - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Pre-Eclampsia - Products under Development by Companies 13
Pre-Eclampsia - Products under Investigation by Universities/Institutes 14
Pre-Eclampsia - Companies Involved in Therapeutics Development 15
A1M Pharma AB 15
Alnylam Pharmaceuticals, Inc. 16
Glenveigh Medical, LLC 17
LFB S.A. 18
Pluristem Therapeutics Inc. 19
VG Life Sciences, Inc. 20
Pre-Eclampsia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
A1M-001 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ALN-AGT - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
antithrombin (recombinant) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
digoxin immune fab - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PLX-PAD - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
RMC-035 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
VG-1177 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Pre-Eclampsia - Dormant Projects 51
Pre-Eclampsia - Product Development Milestones 52
Featured News & Press Releases 52
Mar 22, 2016: A1M Pharma finalizes drug candidate for treating pre-eclampsia and files for substance patent 52
Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Pre-eclampsia 52
Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Pre-eclampsia and Indicates Their Superiority Over Other Cells 53
Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Pre-eclampsia 54
Sep 24, 2015: New clinical trial at SLU treats pre-eclampsia in second-trimester pregnancies 54
Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Pre-eclampsia 55
Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 57
Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Pre-eclampsia (PRESERVE-1) 57
Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Pre-eclampsia 58
Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Pre-eclampsia 58
Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Pre-eclampsia 59
Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Pre-eclampsia 60
Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Pre-Eclampsia, H2 2016 7
Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Pre-Eclampsia - Pipeline by A1M Pharma AB, H2 2016 15
Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 16
Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H2 2016 17
Pre-Eclampsia - Pipeline by LFB S.A., H2 2016 18
Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H2 2016 19
Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Pre-Eclampsia - Dormant Projects, H2 2016 51